ライフサイエンスコーパス: kidney failure

1 0.03); 1 patient in each group had end-stage kidney failure.

2 tor for coronary artery disease, stroke, and kidney failure.

3 become the preferred treatment for end stage kidney failure.

4 attack, stroke and progression to heart and kidney failure.

5 ften associated with pain, hypertension, and kidney failure.

6 nsion, eventually culminating in progressive kidney failure.

7 dulin deficiency precedes but does not cause kidney failure.

8 ically important outcomes, such as death and kidney failure.

9 ns do not form and newborn mice die owing to kidney failure.

10 uremic syndrome may develop that can lead to kidney failure.

11 ed by renal cystic growth and progression to kidney failure.

12 corneal opacities, anemia, proteinuria, and kidney failure.

13 o our understanding and study of preterminal kidney failure.

14 s one of the most common causes of pediatric kidney failure.

15 y of bariatric surgery (BS) in patients with kidney failure.

16 long-term dialysis treatment as a result of kidney failure.

17 l for progression of diabetic nephropathy to kidney failure.

18 glomerulonephritis progressing to end-stage kidney failure.

19 nd died several weeks later, presumably from kidney failure.

20 osclerosis, tubulointerstitial fibrosis, and kidney failure.

21 include a poorly characterized risk of late kidney failure.

22 (AA) kidney donors were at greater risk for kidney failure.

23 form of primary GN and an important cause of kidney failure.

24 123) died of CVD, and 66% (n = 548) reached kidney failure.

25 ntify a locus for this common cause of human kidney failure.

26 gregate with hereditary forms of progressive kidney failure.

27 tant role in the pathophysiology of ischemic kidney failure.

28 conditions such as hypertension and chronic kidney failure.

29 erosis, are prevalent in adults with chronic kidney failure.

30 cular hemolysis, thrombocytopenia, and acute kidney failure.

31 22 years old, 11 years before his death from kidney failure.

32 baseline serum creatinine level or onset of kidney failure.

33 are particularly relevant for patients with kidney failure.

34 f hypertension in patients with diabetes and kidney failure.

35 acking CD2AP die soon after birth because of kidney failure.

36 ant severe glomerulonephritis culminating in kidney failure.

37 lar filtration, and leads to proteinuria and kidney failure.

38 regnant adults aged >/=20 y who did not have kidney failure.

39 timately leads to loss of renal function and kidney failure.

40 ey disease, an important and common cause of kidney failure.

41 d glomerular disease is the leading cause of kidney failure.

42 tinine level, acute kidney injury (AKI), and kidney failure.

43 , yet aged animals display no overt signs of kidney failure.

44 glomerular aneurysm and perinatal death from kidney failure.

45 of the glomerulus and is a leading cause of kidney failure.

46 yielding kidney injury and in some patients, kidney failure.

47 oxalate by lactate dehydrogenase, leading to kidney failure.

48 phropathy to patients at the highest risk of kidney failure.

49 emolytic anemia, thrombocytopenia, and acute kidney failure.

50 initiation of autophagy, cell apoptosis, and kidney failure.

51 hereditary glomerular disease that leads to kidney failure.

52 iscoidal LDLs and HDL particles, and develop kidney failure.

53 re proteinuria, foot process effacement, and kidney failure.

54 atients with both endstage liver disease and kidney failure.

55 ne, a hallmark of cardiovascular disease and kidney failure.

56 dult mice resulted in severe proteinuria and kidney failure.

57 tract are the most common cause of pediatric kidney failure.

58 in progressive kidney damage and ultimately kidney failure.

59 n, including a small increase in the risk of kidney failure.

60 for zero or one versus two copies of GSTM1: kidney failure, 1.66 [1.27 to 2.17]; heart failure, 1.16

61 ion cohorts included 3449 patients (386 with kidney failure [11%]) and 4942 patients (1177 with kidne

62 Risk factors for subsequent kidney failure (13% at 5 years posttransplant) were seru

63 failure [11%]) and 4942 patients (1177 with kidney failure [24%]), respectively.

64 t ureter ligation, causes irreversible right kidney failure 3, 6 or 9 months after AKI.

65 Eight studies (11 models) involved kidney failure, 5 studies (6 models) involved all-cause

66 Diabetes is the leading cause of kidney failure, accounting for >45% of new cases of dial

67 a 22-year-old patient who developed chronic kidney failure after receiving haploidentical HSCT from

68 of PI3Kbeta sensitizes mice to lethal acute kidney failure after TMA injury.

69 pathy (IgAN) represents the leading cause of kidney failure among East Asian populations and the most

70 rome (HUS) is the most common cause of acute kidney failure among US children.

71 e proportion of patients who never developed kidney failure and (2) median number of days alive and f

72 e 0.68 (95% CI, 0.57 to 0.82; P < 0.001) for kidney failure and 0.77 (CI, 0.65 to 0.91; P = 0.0024) f

73 ephron damage and renal fibrosis, leading to kidney failure and a premature death rate of 67% by 9 we

74 otein associated with a higher risk for both kidney failure and all-cause mortality.

75 de-induced increases in indexes of liver and kidney failure and concentrations of myeloperoxidase and

76 l fibrosis surrounding collecting ducts with kidney failure and death by 3-4 weeks of age.

77 In CKD, the risk of kidney failure and death depends on the severity of prot

78 ciated with an increased risk for subsequent kidney failure and death.

79 sts underlying PVN with an increased risk of kidney failure and dialysis.

80 ent of proteinuria, resulting in progressive kidney failure and focal segmental glomerulosclerosis.

81 skin disorder that develops in patients with kidney failure and has been linked to exposure to gadoli

82 a new mechanism of pathologic thrombosis and kidney failure and have immediate implications for treat

83 copy of GSTM1 associated with higher risk of kidney failure and heart failure (adjusted hazard ratio

84 ss of GSTM1 is also associated with incident kidney failure and heart failure, we estimated GSTM1 cop

85 cipients.The incidence of dialysis-dependent kidney failure and infection in the liver transplant pat

86 d their physicians that their early onset of kidney failure and longer period of transplantation and

87 increasingly recognized among patients with kidney failure and may be driven by left heart failure,

88 ointerstitial nephritis is a common cause of kidney failure and may have diverse etiologies.

89 scular events, graft loss and progression of kidney failure and mortality in renal transplant recipie

90 25)I iothalamate GFR, expressed per SD, with kidney failure and mortality.

91 concerns about future increased incidence of kidney failure and other complications of CKD.

92 icated Stx2 as the sole contributor to acute kidney failure and other systemic complications in human

93 Progression to kidney failure and recurrence with graft loss after kidn

94 downward spiral of injury toward progressive kidney failure and should, therefore, be investigated.

95 period, 102 previous kidney donors developed kidney failure and were listed for kidney transplantatio

96 sociated with neurological abnormalities and kidney failure and, as an acid glucocerebrosidase recept

97 urred in 5715 participants without prevalent kidney failure, and 1028 heart failure events occurred i

98 ction, associated with a significant risk of kidney failure, and an abnormal facial expression upon s

99 re autoimmune crescentic glomerulonephritis, kidney failure, and lung hemorrhage due to binding of pa

100 -treated diabetes, congestive heart failure, kidney failure, and older age.

101 procedure in the treatment of patients with kidney failure, and requires collaboration of experts fr

102 ir in models of myocardial infarction, acute kidney failure, and stroke through the action of trophic

103 renal donation because of their own risk of kidney failure; and consideration of genetic testing to

104 In Alberta, Canada, rates of untreated kidney failure are significantly higher in older compare

105 Cy/+ rats with PKD have kidney failure as indicated by a significant increase in

106 mplications including heart disease, stroke, kidney failure, blindness and nerve damage.

107 creatinine associated with a higher risk for kidney failure but a lower risk for all-cause mortality.

108 s of chronic kidney disease include not only kidney failure but also complications of decreased kidne

109 tein, each remained directly associated with kidney failure but differed with respect to their associ

110 Renal ciliopathies are a leading cause of kidney failure, but their exact etiology is poorly under

111 prevent or delay serious sequelae, including kidney failure, cardiovascular disease, and premature de

112 dney disease (CKD) are at increased risk for kidney failure, cardiovascular events, and all-cause mor

113 ast 1-year follow-up; and outcomes of death, kidney failure, cardiovascular events, change in kidney

114 orted on a model that predicted the risk for kidney failure, cardiovascular events, or all-cause mort

115 n monogenetic disorders, is characterized by kidney failure caused by bilateral renal cyst growth.

116 e; 78% were white; 63% were men; and 20% had kidney failure caused by diabetes mellitus.

117 Ia) are reported in four of 17 children with kidney failure caused by renal adysplasia in the absence

118 wheat flour causes a dose-dependent chronic kidney failure characterized by renal tubulointerstitial

119 adverse outcomes (death, dialysis-dependent kidney failure (DDKF), and cardiovascular outcomes) for

120 te increased significantly as their risk for kidney failure decreased, as the payment offered increas

121 After the randomized trial was completed, kidney failure (defined as initiation of dialysis or kid

122 Kidney failure, defined as need for dialysis or preempti

123 Patients with chronic kidney failure--defined as a glomerular filtration rate

124 utcome measure was either death or end-stage kidney failure (dependence on dialysis) at 90 days after

125 , all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocyst

126 The incidence of native kidney failure due to drug-induced toxicity decreased si

127 Over a median follow-up of 24.6 years, 256 kidney failure events occurred in 5715 participants with

128 Eight patients with end-stage kidney failure (five men, three women, mean age 51.7 [SD

129 (2) median number of days alive and free of kidney failure for patients who did not survive, who exp

130 rulonephritis is an important cause of human kidney failure for which the underlying molecular basis

131 The primary outcome was kidney failure-free days during the 28-day period after

132 The median number of kidney failure-free days for patients who did not surviv

133 norepinephrine did not improve the number of kidney failure-free days.

134 Once kidney failure has developed, African-Americans are disa

135 gadolinium contrast agents in patients with kidney failure has markedly decreased, patients with exp

136 l status, myocardial or mesenteric ischemia, kidney failure, hypotension, cardiac tamponade, and limb

137 We describe STEC-associated kidney failure in a 40-year-old patient, including the m

138 icantly increased the rate of progression to kidney failure in a Col4a3(-/-) mouse model of autosomal

139 United States and the leading cause of acute kidney failure in children who develop hemolytic uremic

140 bstructive nephropathy, the leading cause of kidney failure in children, can be anatomic or functiona

141 olytic uremic syndrome, the leading cause of kidney failure in children, often follows infection with

142 chia coli (STEC) is the most common cause of kidney failure in children.

143 hy (HIVAN), the most common cause of chronic kidney failure in HIV-infected patients.

144 he most common genetic disease that leads to kidney failure in humans.

145 ed increased prevalence of IgAN-attributable kidney failure in Northern Europe.

146 Studies of kidney failure in older adults have focused on receipt o

147 ensin-converting enzyme slows progression to kidney failure in patients with Alport syndrome but is n

148 lly validated models for predicting risk for kidney failure in patients with CKD are available and re

149 tests can accurately predict progression to kidney failure in patients with CKD stages 3 to 5.

150 antation plays an important role in treating kidney failure in patients with end-stage liver disease.

151 itial Jak/Stat expression and progression of kidney failure in patients with type 2 diabetic nephropa

152 ve fibrosis are common pathways that lead to kidney failure in proteinuric nephropathies.

153 higher rates of both hyperkalemia and acute kidney failure in the early (1.3% and 2.7%, respectively

154 ge, was associated with an increased risk of kidney failure in the general population.

155 disease (DKD) is the single leading cause of kidney failure in the U.S., for which a cure has not yet

156 chemical studies confirmed and characterized kidney failure in xor-nullizygous mice.

157 d mortality, and both heart failure (HF) and kidney failure incidences are increasing.

158 disease initiation prevented albuminuria and kidney failure, indicating miR-92a inhibition as a poten

159 Progressive kidney failure is a genetically and clinically heterogen

160 An inherited, late-onset form of kidney failure is caused by point mutations in the alpha

161 nformation regarding risk for progression to kidney failure is required for clinical decisions about

162 ns, which usually results in proteinuria and kidney failure, is caused by mutations to the COL4A3, CO

163 D), the most common genetic cause of chronic kidney failure, is characterized by the presence of nume

164 ysis is used in less than 17% of adults with kidney failure, it is the preferred dialysis treatment f

165 renal replacement treatment modalities, and kidney failure itself.

166 ected at an early stage but can cause lethal kidney failure later on.

167 derate (>/=30-< 60), severe (>/=15-<30), and kidney failure (<15 or dialysis).

168 a provide indirect evidence that the risk of kidney failure may be exaggerated in AA donors.

169 1.04 [0.86 to 1.26]), or dialysis-dependent kidney failure (n=343 events; 1.15 [0.93 to 1.43]) compa

170 e dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.

171 Kidney failure occurred in 554 participants (66%), and t

172 E (risk for renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney funct

173 In the kidney, failure of terminal differentiation causes dyspl

174 c kidney disease (CKD), in whom the cause of kidney failure often remains unknown.

175 of cardiovascular mortality in patients with kidney failure on dialysis.

176 the impact of control of diabetes as well as kidney failure on hypertension by combined kidney and pa

177 ients lost pancreatic function subsequent to kidney failure, one secondary to noncompliance and the o

178 transplantation) and a composite outcome of kidney failure or all-cause mortality were ascertained t

179 predictors of risk and the composite outcome kidney failure or creatinine doubling, was developed and

180 The 24-hr urinary samples of patients with kidney failure or on renal replacement therapy were excl

181 (OR, 2.97; 95% CI, 1.83 to 4.81; P<0.0001), kidney failure (OR, 4.77; 95% CI, 1.80 to 12.6; P=0.002)

182 atients who did not survive, who experienced kidney failure, or both was 9 days (interquartile range

183 atients who did not survive, who experienced kidney failure, or both.

184 d-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therap

185 or phrases "nephrotoxicity," "nephropathy," kidney failure," or "renal failure." The identified publ

186 iovascular disease (CVD), heart failure, and kidney failure outcomes.

187 Rates of kidney failure overall (treated and untreated combined)

188 contrast to the dramatic increase in treated kidney failure, overall CKD prevalence in the U.S. popul

189 Moreover, in patients with kidney failure, peritoneal dialysis significantly decrea

190 velop a recessive phenotype characterized by kidney failure, proteinuria, glomerulosclerosis, and ret

191 d its presence in all moribund mice suggests kidney failure rather than the fibrotic heart lesions as

192 ric reflux accounts for approximately 10% of kidney failure requiring dialysis or transplantation, an

193 moderate impairment, severe impairment, and kidney failure, respectively.

194 eGFR, doubling of serum creatinine, AKI, and kidney failure, respectively.

195 ntravital microscopy of animals with chronic kidney failure showed that FGF23 inhibits chemokine-acti

196 7.4 %, of life-threatening bleeding 7.4%, of kidney failure stage III 7.4%, and of major access site

197 in excretion is an important risk factor for kidney failure, stroke, and cardiovascular disease, perh

198 cause participants were more likely to reach kidney failure than death in follow-up.

199 97,451 (5.36%) died, 3295 (0.18%) developed kidney failure that was treated and 3116 (0.17%) develop

200 that was treated and 3116 (0.17%) developed kidney failure that went untreated.

201 etween patients with or without a history of kidney failure, the allelic or genotypic distributions f

202 the impact of the SNPs on dialysis-dependent kidney failure, the incidence of infections and patient

203 For kidney failure, the increased risks were 2.81 (CI, 2.48

204 rticipants' risk for subsequently developing kidney failure themselves, and who would receive the don

205 The prevalence and incidence of kidney failure treated by dialysis and transplantation i

206 The incidence of kidney failure treatment in the United States increased

207 rtality, cardiovascular (CVD) mortality, and kidney failure until December 2000.

208 The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%) in the vas

209 Within each eGFR stratum the rate of treated kidney failure was higher in younger compared with older

210 Age at presentation with kidney failure was later in PKD2 than in PKD1 (median ag

211 athogenesis provoking glomerulonephritis and kidney failure was nonhematopoietic in origin, independe

212 process effacement leads to proteinuria and kidney failure, we studied the function of FAK in podocy

213 Rates of untreated kidney failure were consistently higher at older ages.

214 9 mL/min/1.73 m2), adjusted rates of treated kidney failure were more than 10-fold higher among the y

215 mL/min/1.73 m2, adjusted rates of untreated kidney failure were more than 5-fold higher among the ol

216 rosis is responsible for chronic progressive kidney failure, which is present in a large number of ad

217 n heavy albuminuria, glomerulosclerosis, and kidney failure, which led to animal death beginning at 1

218 of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is pote

219 this is related directly to the treatment of kidney failure with HD or to the higher prevalence of ob

220 life-threatening problem in the treatment of kidney failure with peritoneal dialysis.

221 been identified as the cause for progressive kidney failure with urinary protein loss.

222 st formation, kidney enlargement, and severe kidney failure, with a mean survival time of 2 months.

223 with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative str

224 nockout (KO) mice, which develop spontaneous kidney failure, with that of Col4a3;Tsp1 double-knockout

225 Mice homozygous for the mutation died from kidney failure within 72 hours after birth.

226 kidney disease (DKD) is the leading cause of kidney failure worldwide and the single strongest predic

227 n study of IgA nephropathy, a major cause of kidney failure worldwide.